Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy

Sana Biotechnology's proposed treatment for lupus, SC291, has received fast track designation from the FDA. Developed using Sana's hypoimmune platform, the CD19-directed allogeneic CAR T cell therapy is being evaluated in a trial for B-cell mediated autoimmune diseases.